Xilio Therapeutics, Inc.
NASDAQ:XLO · NASDAQ Global Select
+$0.32 today
Vol 0.04M · Avg 0.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-99.3%
avg 34.0%
ROIC
-42.1%
avg -114.1%
ROA
-22.6%
avg -72.5%
Analysis
ROA is currently the strongest return metric at -22.6% versus its period average of -72.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Rene Russo BCPS | President, Chief Executive Officer & Director | $1.16M | — | 51 | $88,500.00 | 1.35% |
Christopher Frankenfield | Chief Financial Officer & Chief Operating Officer | $941,594.00 | — | 44 | $24,766.00 | 0.38% |
Katarina Luptakova | Chief Medical Officer | $691,670.00 | — | 50 | $33,250.00 | 0.51% |
Uli Bialucha | Chief Scientific Officer | — | — | — | — | — |
Ruth du Moulin | Senior Vice President of Medical Affairs | — | — | — | — | — |
Scott Coleman | Chief Development Officer | — | — | — | — | — |
Kevin Brennan | Senior Vice President of Finance & Accounting | — | — | 56 | $5,000.00 | 0.08% |
Nathan McBride | Chief Information Officer | — | — | — | — | — |
Caroline Hensley | Chief Legal Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$61,538.90
Sells
2
$5,696.18
Net Sentiment
+$55,842.72
Net buying
Most Active
Shannon James Samuel
2 transactions
Analysis
Insiders reported 3 buys worth $61,538.90 and 2 sells worth $5,696.18 over the last 12 months. That adds up to net buying of $55,842.72. Shannon James Samuel was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
PDS Biotechnology Corporation
NASDAQ:PDSB
$58.61M
OnKure Therapeutics, Inc.
NASDAQ:OKUR
$57.43M
Kezar Life Sciences, Inc.
KZR
$53.86M
LAVA Therapeutics N.V.
LVTX
$45.77M
FibroGen, Inc.
FGEN
$36.69M
Aligos Therapeutics, Inc.
ALGS
$32.67M
Actinium Pharmaceuticals, Inc.
ATNM
$31.69M
Skye Bioscience, Inc.
SKYE
$27.67M
Tvardi Therapeutics, Inc.
TVRD
$24.77M
Tempest Therapeutics, Inc.
TPST
$5.60M
Who manages XLO?
Xilio Therapeutics, Inc. (XLO) lists 9 active executives. The top listed executive is Christopher Frankenfield, Chief Financial Officer & Chief Operating Officer.
Are XLO insiders buying or selling?
Recent insider activity shows net buying of $31.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.